Acorda Therapeutics (ACOR) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
August 5, 2021 4:01 PM EDTINBRIJA® (levodopa inhalation powder) Q2 2021 net revenue of $6.4 million; 36% increase over Q2 2020 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q2 2021 net revenue of $21.8 million Agreement to commercialize INBRIJA in Spain with Esteve Pharmaceuticals $69 million of convertible senior notes repaid
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the second quarter 2021.
We were pleased to see a 36% increase in INBRIJA net sales in the second quarter of 2021 over the same period in 2020. We also saw increases in... More
